The PLSP summarizes results from the phase 2/3 KidCOVE trial examining mRNA-1273 (Moderna’s COVID-19 vaccine) in children 6 through 11 years of age This Plain Language Summary of Publication article from Future Virology examines Moderna’s COVID-19 vaccine in children ages 6 to 11. This summary describes a study called KidCOVE which was a Phase 2/3 clinical study, meaning, it tested if the vaccine is safe, produces an immune response, and protects against disease.

You can read the full Plain Language Summary of Publication article here.

This article is based on the original article published in The New England Journal of Medicine called ‘Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age’.

You can read the original article here.